Optiver Holding B.V. Acquires Shares of 421 DexCom, Inc. (NASDAQ:DXCM)

Optiver Holding B.V. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 421 shares of the medical device company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank bought a new position in shares of DexCom in the fourth quarter valued at approximately $385,367,000. Congress Asset Management Co. boosted its position in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD bought a new position in DexCom in the 4th quarter valued at $96,507,000. Jennison Associates LLC increased its position in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares during the last quarter. Finally, ExodusPoint Capital Management LP raised its stake in shares of DexCom by 197.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 466,414 shares of the medical device company’s stock worth $36,273,000 after purchasing an additional 309,714 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock valued at $4,734,384 in the last quarter. Insiders own 0.32% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $71.30 on Wednesday. The stock has a market cap of $27.96 billion, a price-to-earnings ratio of 49.86, a PEG ratio of 2.30 and a beta of 1.50. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business has a 50-day simple moving average of $72.35 and a 200 day simple moving average of $76.70. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $132.26.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on DXCM shares. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Canaccord Genuity Group increased their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price on the stock. Finally, Morgan Stanley increased their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.